101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Nature of Business link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Merger with Mirna Therapeutics link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Available-for-Sale Investments link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Prepaid Expenses and Other Current Assets link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Common Stock link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Preferred Stock link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Equity-based Compensation and Equity Incentive Plans link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Significant Agreements link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Net Loss per Share/Unit link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Related-Party Transactions link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Merger with Mirna Therapeutics (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Available-for-Sale Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Equity-based Compensation and Equity Incentive Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Net Loss per Share/Unit (Tables) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Nature of Business - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Merger with Mirna Therapeutics - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Merger with Mirna Therapeutics - Net Assets Acquired in the Merger (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Available-for-Sale Securities - Summary of Available-for-Sale Securities Held (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Available-for-Sale Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Prepaid Expenses and Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Common Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Preferred Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 LLC Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Awards (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Stock Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Significant Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Net Loss per Share/Unit - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Net Loss per Share/Unit - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Net Loss per Share/Unit - Schedule of Potentially Common Shares/Units Excluded from Calculation of Net Loss Per share/Unit (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Related-Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Merger with Mirna Therapeutics - Net Assets Acquired in the Merger (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink